The transmembrane protein Delta-Like Ligand 3 (DLL3), a member of the Notch ligand family, is expressed in the CT26 cell line. The human DLL3 gene, which has an open reading frame of around 1800 bp, is found on chromosome 19q13. Sixteen epidermal growth factor-like domains, one DSL domain, and one intracellular domain make up the 619 amino acid DLL3 protein. Members of the ligand family have a highly conserved DSL domain at the extracellular domain's N-terminus, which is necessary for binding to Notch receptors. DLL3's intracellular domain is rather brief, and its precise purpose is still unknown.Research has indicated that DLL3 expression is elevated in neuroendocrine tumors, such as small cell lung cancer (SCLC), and low in normal tissues. These findings raise the possibility that DLL3 might be a target for therapeutic intervention.
According to recent studies, DLL3 may engage in intricate tumor regulation mechanisms through interactions with several Notch receptors, displaying both pro- and anti-tumorogenic properties.
The objective of the study was to examine the functional equivalency of Notch ligands DLL1 and DLL3, which are coexpressed in the mouse embryonic presomitic mesoderm. Different abnormalities are caused by mutations in DLL1 and DLL3, even though they co-express. In order to investigate this, DLL1 was swapped out with DLL3 in mice, which showed that DLL3 does not make up for DLL1. In Drosophila wing discs, DLL1 stimulates Notch whereas DLL3 does not. In neither Drosophila nor mice was there any evidence of antagonistic or repressive interactions between DLL1 and DLL3. Their biochemical nonequivalence is partly explained by variations in particular domains of DLL1 and DLL3, according to in vitro investigations. While DLL3 is mostly found in the Golgi apparatus, endogenous DLL1 is present on the surface of presomitic mesoderm cells.
Figure 1. To examine surface expression using Western blotting, immunoprecipitation, and biotinylation, the researchers created DLL3 stable cell lines. (Geffers I, et al., 2007)
1. Tumor Research: Use the Human DLL3 Stable Cell Line - CT26 to look at how Delta-Like Ligand 3 (DLL3) affects the growth and metastasis of cancers, especially neuroendocrine tumors like small cell lung cancer (SCLC).
2. Identification of Therapeutic Targets: Considering that DLL3 expression is low in normal tissues and increased in tumors such as SCLC, explore DLL3's potential as a therapeutic target for intervention in neuroendocrine tumors.
3. Mechanistic Studies: Explain DLL3's dual role in tumor growth regulation by delving into the complex tumor regulatory processes involving it, including its interactions with different Notch receptors.
4. Drug Screening: To find substances that alter DLL3 activity that might be used as therapeutic agents for neuroendocrine tumors, use the Human DLL3 Stable Cell Line - CT26 in drug screening experiments.
Customer Q&As
How stable is this cell line? Will DLL3 expression be lost during long-term culture or multiple passages?
A: This cell line has been verified through multiple passages, and DLL3 expression remains stable. We conducted experiments for 50 consecutive passages, and the expression level of DLL3 was quantitatively analyzed by Western Blot and flow cytometry. The results showed that there was no significant change in the expression of DLL3.
What is the verification method for DLL3 expression? Can you provide experimental data support?
A: DLL3 expression was verified by Western Blot and flow cytometry. Western Blot results showed that in each passage, the DLL3 protein band was clear and the expression level was consistent. Flow cytometry analysis showed that the proportion of DLL3-positive cells was stable at more than 90%. We can provide detailed experimental data and maps for reference.
What types of experiments is this cell line suitable for? Has it been functionally verified?
A: Human DLL3 Stable Cell Line-CT26 is suitable for DLL3-related signaling pathway research, antibody drug screening, immunological research, etc. Functional verification included the role of DLL3 in inhibiting the Notch signaling pathway. We verified the function of DLL3 through the Notch signaling pathway reporter gene system.
Ask a Question
Customer Reviews
Reliable
We were able to learn a lot about tumor biology thanks to this cell line. Our research shed light on DLL3's function in SCLC. Similar to trying to find a needle in a haystack! In addition, the staff at Creative Biogene gave us outstanding assistance all through our research process.
Easy to use
The utilization of the Human DLL3 Stable Cell Line - CT26 revolutionized our drug screening procedures. We found some interesting drugs that might target DLL3 in neuroendocrine tumors. It's similar to winning the lottery in a scientific experiment! Strongly suggest it to anyone working in the industry.
Therapeutic target
Creative Biogene's DLL3 cell line is excellent. Our research on Notch signaling pathways in tumor biology has greatly benefited from it. They are a trusted source in the research community because of their expertise and high-caliber products.
Write a Review